Coya Therapeutics

Biotechnology

Based in TX

Share:𝕏LinkedInFacebook
🤖

AI Overview

With $20K in lobbying spend across 3 quarterly filings, Coya Therapeutics is an active lobbying client. Their lobbying covers 2 issue areas.

$20K
Total Spend
1
Years Active
1
Firms Hired
2
Lobbyists Deployed
2
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2022$20K

Issues Lobbied

Budget/AppropriationsMED

Lobbying Firms

Winning Strategies Washington

Lobbyists

Nancy FOXMichael Merola

Government Agencies Targeted

These are the government entities that Coya Therapeutics disclosed contacting in their lobbying filings.

HOUSE OF REPRESENTATIVESSENATE
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Budget/Appropriations, MED

Funding and other support for research and development of medical therapies, and support for policies that enhance patient access to medical therapies.

Related Analysis

📈 Client Trajectories
See how this client compares to others over time
🎯 Market Concentration
How concentrated is the lobbying market?
🚀 Spending Momentum
Which issues are surging right now?

Related Investigations

The 22,000% ROI
When lobbying spending yields outsized returns.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.

Similar Clients

The University of Texas Md Anderson Cancer Center
$3.5M total spend
University of North Texas System
$1.7M total spend
Baylor Scott and White Health -- Formerly Baylor Health Care System
$813K total spend
Baylor Scott & White Health
$600K total spend
Sonic Healthcare USA
$580K total spend

Explore More

← All Clients⚖️ Compare Clients💵 ROI Calculator🔍 Investigations📖 How Lobbying Works🕸️ Network Analysis🏛️ Agency Pressure

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.